Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 11-12, 2008, Pages 1317-1325

  Mullin, J M ^a,b   Valenzano, M C ^a   Whitby, M ^a   Lurie, D ^c   Schmidt, J D ^b   Jain, V ^b   Tully, O ^b   Kearney, K ^b   Lazowick, D ^a   Mercogliano, G ^b   Thornton, J J ^b  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b LANKENAU HOSPITAL   (United States)

^c SAINT JOSEPH S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; PROTON PUMP INHIBITOR; SUCROSE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPEPSIA; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MUCOSA; HUMAN; MALE; MORNING DOSAGE; PERMEABILITY BARRIER; PRIORITY JOURNAL; SIDE EFFECT; SUCROSE PERMEABILITY TEST; TRANSMUCOSAL LEAK; UPPER GASTROINTESTINAL TRACT;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GASTRIC MUCOSA; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PERMEABILITY; PROTON PUMP INHIBITORS; SUCROSE; YOUNG ADULT;

EID: 55349103040     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03824.x     Document Type: Article

References (42)

1. Cappell MS. Clinical presentation, diagnosis, and management of gastroesophageal reflux disease. Med Clin North Am 2005 89 : 243 91.
2. Tebaldi M, Heading RC. Clinical economics review: functional non-ulcer dyspepsia. Aliment Pharmacol Ther 1998 12 : 11 9.
3. Henry SM. Discerning differences: gastroesophageal reflux and gastroesophageal reflux disease in infants. Adv Neonatal Care 2004 4 : 235 47.
4. Omari TI, Haslam RR, Lundborg P, Davidson GP. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr 2007 44 : 41 4.
5. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2007 5 : 17 26.
6. Maley CC, Rustgi AK. Barrett's esophagus and its progression to adenocarcinoma. J Natl Compr Canc Netw 2006 4 : 367 74.
7. El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002 50 : 368 72.
8. Lanas A. Potent gastric acid inhibition in the management of Barrett's oesophagus. Drugs. 2005 65 (Suppl 1 75 82.
9. Mullin JM, Valenzano MC, Trembeth S, et al. Transepithelial Leak in Barrett's Esophagus. Dig Dis Sci 2006 51 : 2326 36.
10. Meddings JB, Sutherland LR, Byles NI, Wallace JL. Sucrose, a novel permeability marker for gastroduodenal disease. Gastroenterology 1993 104 : 1619 26.
11. Smecuol E, Bai JC, Sugai E, et al. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 2001 49 : 650 5.
12. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000 14 : 1249 58.
13. Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 1996 111 : 1200 5.
14. Menzies IS. Urinary excretion of sugars related to oral administration of disaccharides in adult coeliac disease. Clin Sci 1972 42 : 18P.
15. Munck BG, Rasmussen SN. Paracellular permeability of extracellular space markers across rat jejunum in vitro. Indication of a transepithelial fluid circuit. J Physiol 1977 271 : 473 88.
16. Meddings JB, Wallace JL, Sutherland LR. Sucrose permeability: a novel means of detecting gastroduodenal damage noninvasively. Am J Ther 1995 2 : 843 9.
17. Bergmeyer H, Bernt E. Sucrose, in Methods of Enzymatic Analysis, 2nd edn. New York : Academic Press, 1974.
18. Hassan-Alin M. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000 56 : 665 70.
19. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001 40 : 523 37.
20. Murray LJ, Gabello M, Rudolph DS, et al. Transmucosal gastric leak induced by proton pump inhibitors. Digestive Diseases and Sciences 2008 in press.
21. Hopkins AM, McDonnell C, Breslin NP, O'Morain CA, Baird AW. Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue. J Pharm Pharmacol 2002 54 : 341 7.
22. Yenisehirli A, Onur R. Specific H+/K(+)-ATPase inhibitors decreased contractile responses of isolated rat vas deferens. Pharmacol Res 2006 54 : 397 405.
23. Aydin C, Sarac B, Koyuncu A, Yildirim S, Sen M, Sarioglu Y. Relaxant effect of omeprazole and lansoprazole in guinea pig gallbladder muscle strips in vitro. J Gastroenterol 2003 38 : 765 71.
24. Hotta Y, Fujita M, Nakagawa J, et al. Contribution of cytosolic ionic and energetic milieu change to ischemia- and reperfusion-induced injury in guinea pig heart: fluorometry and nuclear magnetic resonance studies. J Cardiovasc Pharmacol 1998 31 : 146 56.
25. Rhoden KJ. Inhibition of vascular smooth muscle tone by the H+, K+-ATPase inhibitor SCH 28080. J Pharm Pharmacol 2000 52 : 857 62.
26. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem 1998 273 : 29745 53.
27. Fasano A, Fiorentini C, Donelli G, et al. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J Clin Invest 1995 96 : 710 20.
28. Madara JL. Intestinal absorptive cell tight junctions are linked to cytoskeleton. Am J Physiol 1987 253 : C171 5.
29. Clarke H, Soler AP, Mullin JM. Protein kinase C activation leads to dephosphorylation of occludin and tight junction permeability increase in LLC-PK1 epithelial cells sheets. J Cell Sci 2000 113 : 3187 96.
30. Knipp GT, Ho NF, Barsuhn CL, Borchardt RT. Paracellular diffusion in Caco-2 cell monolayers: effect of perturbation on the transport of hydrophilic compounds that vary in charge and size. J Pharm Sci 1997 86 : 1105 10.
31. Mullin JM, Kampherstein JA, Laughlin KV, Saladik dT, Peralta Soler A. Transepithelial paracellular leakiness induced by chronic phorbol ester exposure correlates with polyp-like foci and redistribution of protein kinase C-alpha. Carcinogenesis 1997 18 : 2339 45.
32. Kiley CA, Cragin DJ, Roth BJ. Omeprazole-associated digoxin toxicity. South Med J 2007 100 : 400 2.
33. Welage LS, Berardi RR. Drug interactions with antiulcer agents: considerations in the treatment of acid-peptic disease. J Pharm Pract 1994 7 : 177 95.
34. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999 13 (Suppl. 3 18 26.
35. Homma M, Itagaki F, Yuzawa K, Fukao K, Kohda Y. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation 2002 73 : 303 4.
36. Itagaki F, Homma M, Yuzawa K, et al. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol 2004 56 : 1055 9.
37. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003 63 : 2739 54.
38. Dmochowski R, Chen A, Sathyan G, MacDiarmid S, Gidwani S, Gupta S. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. J Clin Pharmacol 2005 45 : 961 8.
39. Washington C, Hou E, Hughes N, Berner B. Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin. Am J Health Syst Pharm 2006 1 : 63.
40. Choudhry U, Boyce HW Jr., Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998 110 : 615 21.
41. el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997 92 : 1858 60.
42. Larsson H, Carlsson E, Hakanson R, et al. Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1988 95 : 1477 86.